Resources
At Lynx Dx, we’re dedicated to providing providers and families the resources they need to navigate the complexities of prostate cancer. Here you’ll find news, press releases, blog articles, events, research, and other content to support a care journey.
Rethinking Active Surveillance: First Validated Urine Test for Prostate Cancer Monitoring
Active surveillance is widely used to manage men with low-risk prostate cancer, helping avoid unnecessary treatment while monitoring for signs of disease progression.
Can You Prevent Prostate Cancer by Following a Healthy Diet?
Research has added clarity to the relationship between diet and prostate cancer, including the role of antioxidants, phytochemicals, fatty acids, and processed meats.
Cancer Today Spotlights Lynx Dx’s MPS2 as a Breakthrough At-Home Prostate Cancer Test
In a recent feature, Cancer Today explores how MyProstateScore 2.0 (MPS2) may help men avoid unnecessary or [...]
Newly Published Analytical Validation Reinforces Accuracy and Precision of MyProstateScore 2.0
A new peer-reviewed study published in Diagnostics confirms the analytical validity of MyProstateScore 2.0 (MPS2), a urine-based [...]
Bringing Accurate and Flexible Prostate Cancer Insights to AUA2025!
Join the Lynx Dx team at AUA2025, the American Urological Association's annual meeting, April 26-29, 2025.
Lynx Dx Launches Ordering for At-Home Collection Version of MyProstateScore 2.0
MyProstateScore 2.0 (MPS2) will be made available for at-home sample collection.
Lynx Dx Introduces At-Home Collection Option for MyProstateScore 2.0
MyProstateScore 2.0 (MPS2) will be made available for at-home sample collection.
MyProstateScore 2.0 Clinical Validation Using Non-DRE Urine
New peer-reviewed research published in the Journal of Urology validates the use of MPS2 with a non-DRE testing approach.
Lynx Dx Announces Medicare Coverage for MyProstateScore 2.0, Marking a Major Milestone in Prostate Cancer Risk Assessment
Lynx Dx is proud to announce that MyProstateScore 2.0 (MPS2) has been approved for coverage from Medicare.